These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28842311)

  • 1. Structure-based drug design of novel peptidomimetic cellulose derivatives as HCV-NS3 protease inhibitors.
    Saleh NA; Elshemey WM
    Life Sci; 2017 Oct; 187():58-63. PubMed ID: 28842311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of potential inhibitors for HCV NS3 genotype 4a by combining protein-ligand interaction fingerprint, 3D pharmacophore, docking, and dynamic simulation.
    El-Hasab MAE; El-Bastawissy EE; El-Moselhy TF
    J Biomol Struct Dyn; 2018 May; 36(7):1713-1727. PubMed ID: 28531373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing and molecular docking of cyclic peptides against HCV NS3 protease.
    Masoud MS; Bukhari SA; Qasim M; Naqvi SAR; Ashfaq UA
    Pak J Pharm Sci; 2017 Sep; 30(5(Supplementary)):1965-1969. PubMed ID: 29105629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.
    Pillaiyar T; Namasivayam V; Manickam M
    Curr Med Chem; 2016; 23(29):3404-3447. PubMed ID: 27160539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors.
    Matthew AN; Zephyr J; Nageswara Rao D; Henes M; Kamran W; Kosovrasti K; Hedger AK; Lockbaum GJ; Timm J; Ali A; Kurt Yilmaz N; Schiffer CA
    mBio; 2020 Mar; 11(2):. PubMed ID: 32234812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
    Wei HY; Lu CS; Lin TH
    J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide inhibitors of hepatitis C virus NS3 protease.
    Portal-Núñez S; González-Navarro CJ; García-Delgado M; Vizmanos JL; Lasarte JJ; Borrás-Cuesta F
    Antivir Chem Chemother; 2003 Sep; 14(5):225-33. PubMed ID: 14694985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening.
    Wadood A; Riaz M; Uddin R; Ul-Haq Z
    PLoS One; 2014; 9(2):e89109. PubMed ID: 24551230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the inhibitory effect of eight compounds from
    Wei Y; Yang J; Kishore Sakharkar M; Wang X; Liu Q; Du J; Zhang JJ
    Nat Prod Res; 2020 Jun; 34(11):1607-1610. PubMed ID: 30449158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease.
    Belfrage AK; Abdurakhmanov E; Kerblom E; Brandt P; Oshalim A; Gising J; Skogh A; Neyts J; Danielson UH; Sandström A
    Bioorg Med Chem; 2016 Jun; 24(12):2603-20. PubMed ID: 27160057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of ketoamide inhibitors on HCV NS3/4A protease target: molecular docking studies.
    Wadood A; Riaz M; Jamal SB; Shah M
    Mol Biol Rep; 2014 Jan; 41(1):337-45. PubMed ID: 24234753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformer and pharmacophore based identification of peptidomimetic inhibitors of chikungunya virus nsP2 protease.
    Dhindwal S; Kesari P; Singh H; Kumar P; Tomar S
    J Biomol Struct Dyn; 2017 Dec; 35(16):3522-3539. PubMed ID: 27844505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hexapeptide functionality of cellulose as NS3 protease inhibitors.
    Ibrahim M; Saleh NA; Elshemey WM; Elsayed AA
    Med Chem; 2012 Sep; 8(5):826-30. PubMed ID: 22741792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.
    McGivern DR; Masaki T; Lovell W; Hamlett C; Saalau-Bethell S; Graham B
    J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis.
    Xue W; Wang M; Jin X; Liu H; Yao X
    Mol Biosyst; 2012 Oct; 8(10):2753-65. PubMed ID: 22833015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of HCV protease inhibitors.
    Chen KX; Njoroge FG
    Curr Opin Investig Drugs; 2009 Aug; 10(8):821-37. PubMed ID: 19649927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Road Map for the Structure-Based Design of Selective Covalent HCV NS3/4A Protease Inhibitors.
    Shunmugam L; Ramharack P; Soliman MES
    Protein J; 2017 Oct; 36(5):397-406. PubMed ID: 28815420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).
    Seiwert SD; Andrews SW; Jiang Y; Serebryany V; Tan H; Kossen K; Rajagopalan PT; Misialek S; Stevens SK; Stoycheva A; Hong J; Lim SR; Qin X; Rieger R; Condroski KR; Zhang H; Do MG; Lemieux C; Hingorani GP; Hartley DP; Josey JA; Pan L; Beigelman L; Blatt LM
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4432-41. PubMed ID: 18824605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of non-macrocyclic small molecule inhibitors against the NS3/4A serine protease of hepatitis C virus through in silico screening.
    Chaudhuri R; Lee H; Truong L; Torres J; Patel K; Johnson ME
    J Chem Inf Model; 2012 Aug; 52(8):2245-56. PubMed ID: 22697413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.